Quality of life in drug resistant tuberculosis
DOI:
https://doi.org/10.18203/2320-6012.ijrms20222534Keywords:
Drug-resistant Tuberculosis, Adverse drug reactions, Quality of lifeAbstract
Background: India has largest population of drug resistant tuberculosis, the treatment of which is long and full of adverse drug reactions. Despite the ongoing research in clinical and pharmacological aspects, quality of life in drug-resistant tuberculosis remains less explored.
Methodology: This hospital based cross-sectional study done in the at tertiary care center in Surat, from January 2019 to February 2020, enrolling patients above 18 years, with multi-drug/ extensively drug resistant tuberculosis, who suffered > 1 adverse drug reaction after commencing treatment. SF-36 was administered and QOL scores calculated in social, mental and physical domains.
Results: Among the 120 patients studied, majority(87.5%) were had pulmonary tuberculosis. 92.5% and 7.2% were multi-drug resistant and extensively drug resistant respectively. The quality of life was poor in all three domains- physical (25.1), social (39.5)and mental (39.5).
Gender, type of tuberculosis, past history of tuberculosis did not affect the QOL significantly.
Conclusion: Drug-resistant tuberculosis along with its associated adverse drug reactions greatly impacts the quality of life in all domains. Measures need to focus not just on treatment of disease but also the adverse drug reactions, rehabilitation and counselling measures as well.
Keywords: Drug-resistant Tuberculosis, Adverse drug reactions, Quality of life
Metrics
References
Global Tuberculosis Report 2020. Geneva:World Health Organization. 2020.
Pai M., Bhaumik S., Bhuyan S.S. India's plan to eliminate tuberculosis by 2025: converting rhetoric into reality. BMJ Glob Health. 2017;2(2)
WHO . World Health Organization; Geneva: 2016. Global Tuberculosis Report 2016.
World Health Organization. Consolidated Guidelines on Drug- Resistant Tuberculosis Treatment. Geneva: World Health Organization; 2019.
Seung KJ, Keshavjee S, Rich ML. Multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis. Cold Spring Harb Perspect Med. 2015;5:a017863. doi:10.1101/cshperspect.a017863
Thomas BE, Shanmugam P, Malaisamy M, et al. Psycho-socio- economic issues challenging multidrug resistant tuberculosis patients: a systematic review. PLoS One. 2016;11(1):e0147397. doi:10.1371/ journal.pone.0147397
Verma R, Mahor GR, Shrivastva A, Pathak P. Adverse drug reactions associated with first line antitberculosis drugs in a tertiary care teaching hospital: A study of clinical presentations, causality and severity. Asian J Pharm Clin Res. 2014;7:140–3.
Jaber AAS, Khan AH, Sulaiman SAS. Evaluation of health-related quality of life among tuberculosis patients in two cities in Yemen. PLoS One. 2016;11:48:1–19.
Brown J, Capocci S, Smith C, Morris S, Abubakar I, Lipman M. Health status and quality of life in tuberculosis. Int J Infect Dis. 2015;32:68–75. doi: 10.1016/j.ijid.2014.12.045.
Louw J, Peltzer K, Naidoo P, Matseke G, McHunu G, Tutshana B. Quality of life among tuberculosis (TB), TB retreatment and/or TB-HIV co-infected primary public health care patients in three districts in South Africa. Health Qual Life Outcomes. 2012;10:77. doi: 10.1186/1477-7525-10-77.
Sharma R, Yadav R, Sharma M, Saini V, Koushal V. Quality of life of multi drug resistant tuberculosis patients: a study of North India. Acta Medica Iranica. 2014;52(6):448–453.
Central TB Division, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, New Delhi. RNTCP Technical and Operational Guidelines for TB Control in India. 2016
Ahmad N, Javaid A, Syed Sulaiman SA, Basit A, Afridi AK, Jaber AAS, et al. (2016) Effects of Multidrug Resistant Tuberculosis Treatment on Patients’ Health Related Quality of Life: Results from a Follow Up Study. PLoS ONE 11(7): e0159560. doi:10.1371/journal.pone.0159560
Sineke T, Evans D, Schnippel K, et al. The impact of adverse events on health-related quality of life among patients receiving treatment for drug-resistant tuberculosis in Johannesburg, South Africa. Health Qual Life Outcomes. 2019;17(1):94. Published 2019 May 31.
Alene KA, Clements ACA, McBryde ES, et al. Mental health disorders, social stressors, and health-related quality of life in patients with multidrug-resistant tuberculosis: a systematic review and meta-analysis. J Infect. 2018;77(5):357–367. doi: 10.1016/j.jinf.2018.07.007
Datta S, Gilman RH, Montoya R, et al. Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study. Eur Respir J. 2020;56(2):1900495. doi: 10.1183/13993003.00495-2019
Laxmeshwar C., Stewart A.G., Dalal A., Kumar A.M.V., Kalaiselvi S., Das M. Beyond 'cure' and 'treatment success': quality of life of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(1):73–81.
Salehitali S, Noorian K, Hafizi M, Dehkordi AH. Quality of life and its effective factors in tuberculosis patients receiving directly observed treatment short-course (DOTS). J Clin Tuberc Other Mycobact Dis. 2019 Feb 8;15:100093. doi: 10.1016/j.jctube.2019.100093. PMID: 31720420; PMCID: PMC6830121.
Downloads
Published
How to Cite
Issue
Section
